- 2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
- 2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
- 2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies
- Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
2Seventy Bio Inc (TSVT:NSQ) closed at 13.59, 37.13% above the 52 week low of 9.91 set on Jun 16, 2022.
9.91Jun 16 202234.00Dec 09 2021
Markit short selling activity
|Market cap||547.90m USD|
|EPS (TTM)||-9.53 |
Data delayed at least 15 minutes, as of Dec 09 2022 21:00 GMT.